| Cat. No. |
Size |
Price |
Figures |
|---|
RP10224-0.5 mg
| 0.5 mg | $ 52.25 | MSDS: 20080727040626 (PDF)
HPLC: 20050919140131 (PDF)
MASS SPECE: 20050919140153 (PDF)
References:
- O'Byrne KJ, et al. Phase II study of RC-160 (vapreotide), an octapeptide analogue of somatostatin, in the treatment of metastatic breast cancer. Br. J. Cancer. Mar 1999; 79(9-10): 1413-1418.
- Gonzalez-Barcena D, et al. Response of patients with advanced prostatic cancer to administration of somatostatin analog RC-160 (vapreotide) at the time of relapse. Prostate. Aug 1 2003; 56(3): 183-191.
|
|---|
| Full Name | |
Sequence
(three-letter code) | {d-PHE}{CYS}{TYR}{d-TRP}{LYS}{VAL}{CYS}{TRP}-NH2 |
|---|
| C-Terminal | NH2 |
|---|
| Chemical Bridge | Disulfide bridge: Cys2-Cys7 |
|---|
| Description | RC-160 (octastatin/vapreotide) is a potent octapeptide analogue of somatostatin with growth inhibitory activity in experimental tumors in vitro and in vivo, including breast cancer. High-dose RC-160 can reduce serum levels of the breast growth factors IGF-I and prolactin but is ineffective in the management of metastatic breast cancer. Encouraging preclinical anti-tumor activity and the favourable toxicity profile in patients suggest the merit of future studies combining RC-160 with anti-oestrogen, cytotoxic and anti-angiogenic agents. |
|---|
| Solubility | Soluble in water. The contents of this vial have been accurately determined. Both the stopper and the vial have been siliconized. Do not attempt to weight out a smaller portion of the contents. |
|---|
| Formula | C57H70N12O9S2 |
|---|
| M.W. | 1131.4 |
|---|
| Cas | 103222-11-3 |
|---|
| Purity | > 95% |
|---|
| Storage | Before using, store the peptide in the DRY form at 0 - 5°C. For best and repeatable results, rehydrate the peptide immediately before using. Do not re-freeze any unused portions. |
